Microglia in early disease stages
K Kingwell - Nature Reviews Neurology, 2012 - nature.com
K Kingwell
Nature Reviews Neurology, 2012•nature.comIncreasing evidence suggests that early treatment is essential for efficacy of therapeutic
intervention in neurodegenerative diseases such as Alzheimer disease (AD) and Parkinson
disease (PD). Two new studies have highlighted a key role for microglia-mediated CNS
inflammation in the initial stages of neurodegenerative pathology, suggesting promising
therapeutic targets and strategies for early diagnosis.In a paper published in The Journal of
Neuroscience, Linda Van Eldik and colleagues investigated the therapeutic potential of a …
intervention in neurodegenerative diseases such as Alzheimer disease (AD) and Parkinson
disease (PD). Two new studies have highlighted a key role for microglia-mediated CNS
inflammation in the initial stages of neurodegenerative pathology, suggesting promising
therapeutic targets and strategies for early diagnosis.In a paper published in The Journal of
Neuroscience, Linda Van Eldik and colleagues investigated the therapeutic potential of a …
Increasing evidence suggests that early treatment is essential for efficacy of therapeutic intervention in neurodegenerative diseases such as Alzheimer disease (AD) and Parkinson disease (PD). Two new studies have highlighted a key role for microglia-mediated CNS inflammation in the initial stages of neurodegenerative pathology, suggesting promising therapeutic targets and strategies for early diagnosis.
In a paper published in The Journal of Neuroscience, Linda Van Eldik and colleagues investigated the therapeutic potential of a small-molecule investigational drug, MW-151, in an APP/PS1 knock-in mouse model of AD. MW-151 inhibits the production of proinflammatory cytokines by microglia in reponse to amyloid-β (Aβ) and, importantly, APP/PS1 mice show age-dependent increases in amyloid pathology and CNS inflammation.
nature.com